GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures

Phase 3

Completed

Conditions: Epilepsy

Interventions: Drug: Retigabine IR

First Posted Date: 2013-01-28

Last Posted Date: 2020-03-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 30

Registration Number: NCT01777139

Locations: 🇹🇭
GSK Investigational Site, Khon Kaen, Thailand

Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 Years

Phase 3

Completed

Conditions: Herpes Zoster

Interventions: Biological: Herpes zoster vaccine GSK1437173A

First Posted Date: 2013-01-28

Last Posted Date: 2018-10-25

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 60

Registration Number: NCT01777321

Locations: 🇯🇵
GSK Investigational Site, Fukuoka, Japan

Acceptability of Hepatitis B Vaccination in General Practitioners and Paediatricians

Completed

Conditions: Hepatitis B

Interventions: Other: Data collection

First Posted Date: 2013-01-28

Last Posted Date: 2013-02-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 474

Registration Number: NCT01777074

Locations: 🇫🇷
GSK Investigational Site, Zillisheim, France

An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184

Phase 2

Terminated

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: GSK2586184 50 mg
Drug: GSK2586184 400 mg
Drug: GSK2586184 100 mg
Drug: GSK2586184 200 mg
Drug: Placebo

First Posted Date: 2013-01-28

Last Posted Date: 2017-04-26

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 51

Registration Number: NCT01777256

Locations: 🇸🇪
GSK Investigational Site, Linköping, Sweden

Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination

Phase 3

Completed

Conditions: Infections, Meningococcal

Interventions: Biological: Meningococcal conjugate vaccine GSK134612

First Posted Date: 2013-01-28

Last Posted Date: 2019-01-25

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 156

Registration Number: NCT01777308

Locations: 🇦🇺
GSK Investigational Site, Subiaco, Western Australia, Australia

The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Umeclidinium/Vilanterol 62.5/25 mcg
Drug: Tiotropium 18 mcg

First Posted Date: 2013-01-28

Last Posted Date: 2018-01-24

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 905

Registration Number: NCT01777334

Locations: 🇪🇸
GSK Investigational Site, Valencia, Spain

Development of Read-outs in Healthy, Hepatitis B Virus Naive Adults Vaccinated With the Hepatitis B Surface Antigen (HBsAg) in Combination With a GlaxoSmithKline (GSK) Biologicals' Adjuvant System

Phase 2

Completed

Conditions: Hepatitis B

Interventions: Biological: Adjuvanted Hepatitis B surface antigen (HBsAg) candidate vaccine GSK2231392A.
Biological: EngerixTM-B
Biological: Placebo